COVID-19 Clinical Research.
BCG
COVID-19
Convalescent plasma
Cytokine storm
Immunomodulatory
Immunosuppression
SARS-CoV-2
Vaccines
Journal
Journal of cellular signaling
ISSN: 2692-0638
Titre abrégé: J Cell Signal
Pays: United States
ID NLM: 101767200
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
entrez:
2
7
2020
pubmed:
2
7
2020
medline:
2
7
2020
Statut:
ppublish
Résumé
While the global COVID-19 pandemic has challenged the entire humanity and health systems, it also triggered researchers to urgently perform clinical trials to assess the safety and efficacy of many agents and modalities to combat COVID-19. As of April 22, over 650 clinical studies have been registered both in USA and internationally. Results from these studies are also coming at a brisk pace in this unprecedented emergency. We searched the NCI website and Medline and summarize various national and international clinical trials and summarize few of the pivotal ones in this paper, including those specific to oncology population. Two hundred and eighty four studies are actively recruiting adults and children with confirmed COVID-19, including 25 are early-phase I/phase I, 72 phase II, 58 phase III, 12 phase IV, and 31 other trials. They can be categorized into four groups: drugs that combat SARS-CoV-2, immunomodulatory agents to counteract cytokine storm, convalescence plasma therapies and vaccines trials. It is hoped that these efforts will results in a successful treatment to COVID-19, especially in a timely fashion before the second pandemic expected in fall. It is essential to acknowledge the devotion and hard work of the clinical research team and clinical research volunteers.
Identifiants
pubmed: 32607505
doi: 10.33696/Signaling.1.006
pmc: PMC7326327
mid: NIHMS1601447
doi:
Types de publication
Journal Article
Langues
eng
Pagination
23-30Subventions
Organisme : NCI NIH HHS
ID : UG1 CA189850
Pays : United States
Références
N Engl J Med. 2020 May 21;382(21):1969-1973
pubmed: 32227757
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
Cell Res. 2020 Mar;30(3):269-271
pubmed: 32020029
MMWR Morb Mortal Wkly Rep. 2020 Apr 17;69(15):458-464
pubmed: 32298251
J Infect Dis. 2015 Jan 1;211(1):80-90
pubmed: 25030060
Int J Antimicrob Agents. 2020 Mar 20;:105949
pubmed: 32205204
N Engl J Med. 2020 Mar 5;382(10):929-936
pubmed: 32004427
Clin Infect Dis. 2020 Mar 09;:
pubmed: 32150618
N Engl J Med. 2019 Dec 12;381(24):2293-2303
pubmed: 31774950
Virol J. 2005 Aug 22;2:69
pubmed: 16115318
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
Cell. 2020 May 28;181(5):1036-1045.e9
pubmed: 32416070
Cell Discov. 2020 Mar 16;6:14
pubmed: 32194980
JAMA. 2020 Mar 27;:
pubmed: 32219428
J Med Virol. 2020 Jun;92(6):556-563
pubmed: 32104907
Nat Rev Immunol. 2020 May;20(5):269-270
pubmed: 32273594